Search the GHTC website

Global health R&D delivers for New York

US government investment in global health R&D has delivered

$3.7 billion
to New York research institutions
38,800+ new jobs
for New York
New York's top USG-funded global health R&D institutions

New York's top USG-funded global health R&D institutions

IAVI (formerly International AIDS Vaccine Initiative)
$711.9 million
New York University School of Medicine
$669.6 million
$602.4 million
Weill Cornell Medicine
$260.5 million
Yeshiva University (including Albert Einstein College of Medicine)
$253.8 million
Icahn School of Medicine at Mount Sinai
$157.4 million
Columbia University
$142 million
Population Council
$114.6 million
Rockefeller University
$103.4 million
TB Alliance
$89.4 million
Sloane-Kettering Institute for Cancer Research
$87.4 million
Cornell University
$82.1 million
University of Rochester
$69.9 million
Wadsworth Center, New York State Department of Health
$46 million
State University of New York, Buffalo
$37.3 million
State University of New York, Stony Brook
$31.9 million
Columbia University Irving Medical Center (formerly Columbia University Health Sciences, including Aaron Diamonds AIDS Research Center)
$27.6 million
New York Blood Center
$25.2 million
Trudeau Institute Inc.
$15.9 million
Siga Technologies
$15.5 million
Chembio Diagnostic Systems Inc.
$11.5 million
Starks Associates
$10.6 million
Ecohealth Alliance Inc.
$8.9 million
$8.2 million
Upstate Medical University
$7.8 million
Thermal Gradient*
$7.3 million
Rensselaer Polytechnic Institute
$6.7 million
The New York State Psychiatric Institute
$5.9 million
Albany Medical College
$5.8 million
Brooklyn College
$5.8 million
State University of New York, Albany
$5.6 million
Brookhaven Science Associates
$4.8 million
Avatar Medical LLC
$4.5 million
Codagenix Inc.
$3.8 million
amfAR, The Foundation for AIDS Research
$3.3 million
Abcombi Biosciences
$3 million
Feinstein Institutes for Medical Research
$3 million
MicroRid Technologies*
$3 million
United Biomedical Inc.
$2.4 million
City College of New York
$2.3 million
Jan Biotech
$2.3 million
St. Luke's-Roosevelt Institute for Health Sciences*
$2.2 million
State University of New York, Binghamton
$1.9 million
Global HIV Vaccine Enterprise*
$1.8 million
Ingenious Targeting Laboratory
$1.6 million
New York Medical College
$1.5 million
Curia (formerly Albany Molecular Research Inc.)
$1.4 million
Detect Biosciences
$1.3 million
General Electric Global Research Center
$1.3 million
POP Biotechnologies
$1.3 million
Quicksilver Biosciences
$1.3 million
Roswell Park Comprehensive Cancer Center
$1.2 million
State University of New York, Geneseo
$1.1 million
$1 million
St. John's University
$981 thousand
The City University of New York (including the Advanced Science Research Center, Graduate School of Public Health & Health Policy)
$798 thousand
Chemitope Glycopeptide
$682 thousand
Sapience Therapeutics
$612 thousand
SUNY Downstate Medical Center
$607 thousand
Hunter College
$594 thousand
New York Genome Center
$586 thousand
Medidata Solutions
$530 thousand
$515 thousand
Anacor Pharmaceuticals*
$492 thousand
$430 thousand
Ichor Biologics
$406 thousand
Vital Strategies
$393 thousand
Chronus Pharmaceuticals
$347 thousand
Esper Biosciences
$324 thousand
Tornado Therapeutics
$300 thousand
Pulmokine Inc.*
$283 thousand
Inso Biosciences (formerly Tico Bio)
$271 thousand
Queens College, City University of New York
$253 thousand
OrthoSystems Inc.*
$223 thousand
Hospital for Special Surgery
$222 thousand
Ascribe Bioscience
$150 thousand
Lab11 Therapeutics
$138 thousand
Innovative Biotechnologies International*
$136 thousand
Junco Labs LLC*
$136 thousand
TechnoVax Inc.
$123 thousand
Syracuse University
$110 thousand
Baruch College
$84 thousand
Bronx-Lebanon Hospital Center
$36 thousand
Health Research Inc.
$31 thousand
New York Academy of Sciences
$8 thousand

New York's top areas of global health R&D by USG funding

Flioviral diseases (including Ebola, Marburg)
Neglected tropical diseases
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
Arenaviral hemorrhagic fevers (including Lassa fever)
Bacterial pneumonia & meningitis
Bunyaviral diseases (including CCHF, RVF, SFTS)
Cryptococcal meningitis
Diarrheal diseases
Emergent non-polio enteroviruses (including EV71, D68)
Henipaviral diseases (including Nipah)
Hepatitis B
Hepatitis C
Multi-disease/health area R&D
Other coronaviruses (including MERS, SARS)
Reproductive health
Rheumatic fever
Salmonella infections
Global health R&D at work in New York

New York State houses the headquarters of three nonprofit product development partnerships dedicated to advancing vaccines, drugs, and other global technologies with public health as the goal rather than profit. IAVI, formally known as the International AIDS Vaccine Alliance, is advancing vaccines for HIV, tuberculosis (TB), and emerging infectious diseases, including Lassa fever, Marburg, and Ebola Sudan. TB Alliance’s mission is to advance better, faster, and more affordable TB cures. The alliance developed the world’s first child-friendly TB treatments, as well as a groundbreaking new drug for highly drug-resistant tuberculosis that is now in use both globally and in the United States. Finally, Population Council works to expand contraceptive options. The organization has brought to market innovations, including a one-year, self-removable contraceptive ring, and is advancing other potential breakthroughs, including male contraception and dual-purpose prevention technologies that protect against unintended pregnancy and sexually transmitted infections at the same time.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: International AIDS Vaccine Initiative